Cilastatin does not affect Carba NP test performance for detection of carbapenemase production in Enterobacteriaceae.

Wien Klin Wochenschr

Institute of Hygiene, Microbiology and Tropical Medicine, National Reference Centre for Nosocomial Infections and Antimicrobial Resistance, Elisabethinen Hospital Linz, Fadingerstraße 1, 4020, Linz, Austria.

Published: January 2017

The Carba NP test is a simple confirmation method for carbapenemase-producing Enterobacteriaceae (CPE) but reagents have to be freshly prepared as imipenem sodium salt is unstable. We evaluated the Carba NP test performance based on a commercially available 10-fold cheaper drug formulation containing cilastatin against 217 CPE and 78 non-CPE isolates with reduced meropenem susceptibility. Specificity and sensitivity were 100 % and 98.6 %, respectively and 3 false negative results of blaVIM-1-producing Proteus mirabilis were reproducible with the RAPIDEC® Carba NP test. Cilastatin does not disturb test performance provided that the imipenem drug quantity is doubled.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00508-016-1106-6DOI Listing

Publication Analysis

Top Keywords

carba test
16
test performance
12
test
5
cilastatin affect
4
carba
4
affect carba
4
performance detection
4
detection carbapenemase
4
carbapenemase production
4
production enterobacteriaceae
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!